Abstract
Quality of life was measured in a study of two multidrug regimens for mycobacterium avium complex MAC bactaeremia using the MOS-HIV questionnaire. The effect of treatment on quality of life was estimated at each follow-up time in three ways: (1) using only the observed data, (2) after assigning the worst possible quality of life scores for individuals who died, and (3) after imputing missing scores for patients who either died or dropped out of the study. The overall quality of life scores were also compared between treatment groups with categorical generalized estimating equation models and three-dimensional graphs. Of the 179 patients included in these analyses, 84 (47%) either died or dropped out during the 16 week study period. When the quality of life scores were compared between the treatment groups with the Wilcoxon rank sum test using only the observed data, there was no significant difference between the groups at 16 weeks of follow-up. When the worst possible quality of life scores were assumed for patients who had died, both the magnitude and the statistical significance of the difference in the quality of life scores between the groups increased. Imputing missing data for patients who either dropped out or died resulted in even larger differences in quality of life between the treatment groups. We conclude that ignoring missing data due to drop-outs and death can result in an underestimation of the treatment effect and overly optimistic statements about the outcome of the participants on both treatment arms due to the selective drop-out of participants with poorer quality of life. To obtain a valid assessment of the effect of treatment on quality of life, the experience of the patients who died or dropped out of the study must be considered.
Similar content being viewed by others
References
Shafran S, Singer J, Zarowny DP, et al. Rifabutin, ethambutol and clarithromycin versus rifampin, ethambutol, clofazimine and ciprofloxacin for mycobacterium avium complex bacteraemia in AIDS patients: a prospective, randomized, multicenter, comparative trial (CTN 010). N Engl J Med 1996; 335: 377-383.
Bozzette SA, Kanouse DE, Berry S, Duan N. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. J Am Med Assoc 1995; 273: 295-301.
Gelber RD, Lenderking WR, Cotton DJ, et al. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Intern Med 1992; 116: 961-966.
Bozzette SA, Kanouse DE, Duan N, Berry S, Richman DD. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. Antiviral Ther 1996; 1: 21-32.
Wu AW, Mathews WC, Brysk LT, et al. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-relatedcomplex. J AIDS 1990; 3: 683-690.
Wu AW, Rubin HR, Mathews et al. Functional status and well being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. J AIDS 1993; 6: 452-458.
Heyting A, Tolboom JTBM, Essers JGA. Statistical handling of drop-outs in longitudinal clinical trials. Stat Med 1992; 11: 2043-2061.
Finkelstein DM, Schoenfeld DA. AIDS Clinical Trials, Guidelines for Design and Analysis. New York: John Wiley & Sons, (1995).
Gelber RD, Cole BF, Gelber S, Goldhirsch A. Comparing treatments using quality-adjusted survival: the Q-TWiST method. Am Stat 1995; 49: 161-169.
Bozzette SA, Duan N, Berry S, Kanouse DE. Analytic difficulties in applying quality of life outcomes to clinical trials of therapy for HIV disease. Psychol Health 1994; 9: 143-156.
Schumacher M, Olschewski M, Schulgen G. Assessment of quality of life in clinical trials. Stat Med 1991; 10: 1915-1930.
Zwinderman AH. Statistical analysis of longitudinal quality of life data with missing measurements. Qual Life Res 1992; 1: 219-224.
Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic mycobacterium avium complex (MAC) disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905-911.
Wu AW, Lichter SL, Richardson W et al. Quality of life in patients receiving clarithromycin for mycobacterium avium complex infection and AIDS. Eighth International Conference on AIDS/III STD World Congress. 1992.
Lipsitz SR, Kim K, Zhao L. Analysis of repeated categorical data using generalized estimating equations. Stat Med 1994; 13: 1149-1163.
Greenlees JS, Reece WS, Zieschang KD. Imputation of missing values when the probability of response depends on the variable being imputed. JASA 1982; 77: 251-261.
Safrin S, Finkelstein DM, Feinberg J et al. Comparison of three regimens for treatment of mild to moderate pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. Ann Intern Med 1996; 124: 792-802.
The SOCA Research Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996; 114: 23-33.
Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decision Making 1989; 9: 142-149.
Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics 1989; 45: 781-795.
Raboud JM, Montaner JSG, Thorne A, Singer J, Schechter MT. The impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV infected individuals. J AIDS 1996; 12: 46-55.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raboud, J.M., Singer, J., Thorne, A. et al. Estimating the effect of treatment on quality of life in the presence of missing data due to drop-out and death. Qual Life Res 7, 487–494 (1998). https://doi.org/10.1023/A:1008870223350
Issue Date:
DOI: https://doi.org/10.1023/A:1008870223350